Bioniz Therapeutics has reported positive top-line results from a Phase Ib clinical trial of BNZ-1 to treat Alopecia Areata (AA), a common, inflammatory, immune-mediated hair loss that leads to partial or complete loss of hair on the scalp and body.

The randomised, placebo-controlled trial was designed to analyse the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of various multiple doses of intravenous BNZ-1.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the trial, BNZ-1 was administered to healthy adult subjects.

The trial evaluated three weekly dose cohorts and two alternate weekly dose cohorts in a dose-escalation manner.

“These results establish initial clinical validation of BNZ-1’s potential to treat a variety of IL-2/9/15 cytokine-driven conditions with a novel mechanism.”

It did not find any serious or severe adverse events (AEs), infusion-related reactions, or dose limiting laboratory toxicities.

According to Bioniz, the rate of adverse events reported in the trial was comparable between the pooled BNZ-1 and pooled placebo groups.

Sore throat and runny nose were found to be the only two common adverse events that happened more frequently in the overall BNZ-1 group, compared to the pooled placebo group.

Among other findings, the trial did not observe any dose / exposure-related adverse events.

Bioniz Therapeutics chief medical officer Paul Frohna said: “This Phase Ib study further characterises BNZ-1’s encouraging safety and tolerability profile while producing sustained, dose-dependent, and highly IL-2 / 15-specific pharmacodynamic effects with multiple dosing.

“These results establish initial clinical validation of BNZ-1’s potential to treat a variety of IL-2/9/15 cytokine-driven conditions with a novel mechanism.”

In addition, Bioniz has dosed a total of 53 healthy adult volunteers with BNZ-1 across two Phase I trials. So far, the trials have not observed any dose-limiting side effects, infusion reactions, or serious / severe adverse events.